The stock of Stryker Corporation shows potential for growth with its comprehensive offerings in medical technology. As a prominent player in the healthcare sector, Stryker is well-positioned to capitalize on technological advancements and the increasing demand for innovative medical solutions. However, potential investors should consider the competitive landscape and regulatory risks associated with the medical devices industry.
The current fundamental rating for Stryker Corporation stands at a favorable B+. Below is a detailed breakdown of relevant financial scores:
Category | Score | Visualization |
---|---|---|
Overall | 3 | |
Discounted Cash Flow | 4 | |
Return on Equity | 4 | |
Return on Assets | 5 | |
Debt to Equity | 2 | |
Price to Earnings | 1 | |
Price to Book | 2 |
The historical data shows the evolution of Stryker's financial performance over time, providing insights for strategizing future investments.
Date | Overall | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-06-18 | 3 | 4 | 4 | 5 | 2 | 1 | 2 |
Previous | 0 | 4 | 4 | 5 | 2 | 1 | 2 |
Analysts offer optimistic projections for Stryker’s stock with detailed price targets reflecting the stock’s potential movement.
High | Low | Median | Consensus |
---|---|---|---|
$450 | $403 | $436 | $431.25 |
Overall, analysts maintain a positive sentiment towards Stryker, indicative of confidence in its strategic growth plans.
Recommendation | Count | Visualization |
---|---|---|
Strong Buy | 1 | |
Buy | 35 | |
Hold | 13 | |
Sell | 0 | |
Strong Sell | 0 |
Stryker Corporation holds a well-defined position in the healthcare market with a robust fundamental performance. Its diversified product offerings and consistent innovation make it appealing to investors. However, careful monitoring of market trends and regulatory changes is necessary to navigate potential risks effectively. The positive analyst sentiment and favorable price targets indicate promising future prospects, though competition remains a key factor to watch.